Development
STAT Therapeutics, Inc
Thomas Krol, BS, Pharm.D, CLP, RPh, STAT Therapeutics, Inc. has been starting and managing life science start-ups for over 20 years. He has experience in biopharma as a scientist in research and development (R&D), innovation, marketing and business development. His passion is to deliver the promise of new scientific discoveries to people who can benefit from them. He currently serves in Executive Management at several startups. He was previously Managing Director at the Kansas Bioscience Authority (KBA), a $581 million fund, where he led the human health investment activities at KBA. Tom has directly contributed to the successful development and commercialization of more than 20 biopharma products, including celecoxib (Celebrex®), injectable ziprasidone (Geodon®), vigabatrin (Sabril®), fexofenadine (Allegra®), diltiazem (Cardizem®), doxacurium (Nuromax®), and others. He has worked for bigpharma companies such as Burroughs Wellcome (now GSK), Marion Labs (now Sanofi), and Searle (now Pfizer) and start-ups including CyDex (now Ligand), Clara Biotech and others. Tom serves on the board of directors and advisory board for several companies, and has served on numerous life science company boards. He has a B.S. in pharmacy from Ferris State University and PharmD from the University of Utah. He completed a residency at the University of Utah and a fellowship in clinical drug development at the University of North Carolina and the Burroughs Wellcome Company. He is a registered pharmacist and certified licensing professional, as designated by the Licensing Executives Society.